Recombinant Factor C Assay a Sustainable Endotoxin Testing Solution
Recombinant factor C (rFC) assay is a synthetic equivalent of Factor C and is the first component of the horseshoe crab clotting cascade, which is activated in response to endotoxins. Moreover, the horseshoe crab blood can be collected only during a short time frame, thus limiting its supply considerably. Hence, healthcare companies in the recombinant factor C assay market are increasing their focus on rFC methods to help alleviate this challenge and improve outcomes.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111659
Novel rFC methods are benefitting healthcare companies, as these companies can limit their reliance on animals or any other source materials. Hence, recombinant factor C assay is acquiring popularity as a sustainable solution for endotoxin testing. Such advancements have led to the growth of the recombinant factor C assay market, where the market is estimated to reach a revenue of ~US$ 28 Mn by the end of 2027. Analysts of opine that rFC will gain recognition in the endotoxin testing industry for its accuracy and specificity, which is as good as the LAL (Limulus Amebocyte Lysate) assay.
PyroGene rFC Benefits Pharmaceutical Companies Due to Single-step Enzymatic Process
PyroGene™ recombinant factor C assay is gaining market prominence as a single-step enzymatic process as opposed to LAL assay that involves multiple procedural steps. As such, the PyroGene brand is anticipated to dictate the highest revenue as compared to EndoNext in the recombinant factor C assay market where the market is predicted to grow at a favorable CAGR of ~9% during the forecast period. Monitoring samples for contaminants play a pivotal role in pharmaceutical and medical device industries. This explains why the revenue of pharmaceutical companies is estimated to be the highest among all end users in the market landscape.
Traditional LAL testing is largely dependent on the blood of the horseshoe crab namely Limulus polyphemus. However, multiple enzymatic steps associated with LAL assay is majorly dependent on the availability of horseshoe crabs. Hence, companies in the recombinant factor C assay market are increasing their research spending in PyroGene recombinant factor C assay that can be associated with innovative software systems to gain a read-incubate-read sequence within the workflow.
Consolidated Nature of Market to Attract Attention of Healthcare Giants
LAL assays are considered as the gold standard for endotoxin testing. However, advantages of recombinant factor C assay are transforming the market landscape, which is dictated by only two major companies. Lonza Group— a leading Swiss multinational biotechnology company is increasing efforts to make its PyroGeneTM recombinant factor C assay a compendial method in Europe by collaborating with the European Pharmacopoeia. On the other hand, Hyglos GmbH— a bioMérieux company, which is a global player in in vitro diagnostics, is increasing efforts to reduce the incidence of false positives from ß-Glucan or interference due to colored or turbid samples. Thus, healthcare companies worldwide should tap opportunities in rFC, since the recombinant factor C assay market is consolidated.
Get a glimpse of the in-depth analysis through our Report Brochure
Companies in the recombinant factor C assay market are reducing the pressure on LAL assays for innovations in monitoring samples for contaminants in pharmaceutical products. However, lack of long-term studies that validate rFC for combination testing of unknown samples, inter-laboratory, -operator, and -lot changes poses a barrier for market growth. Hence, pharmaceutical test users are increasing their efficacy in research studies to validate successful outcomes of rFC in specific products.
View full report@ https://qyresearchmedical.com/report/recombinant-factor-c-assay-market-brand-pyrogene-pyrogene-bulk-rfc-2880-tests-and-pyrogene-rfc-192-tests-and-endonext-endozyme-ii-endozyme-ii-go-and-endolisa-and-end-user-pharmaceutical-companies-bio-019-2030/111659
Effective FDA-approved Drug Builds Credibility of Healthcare Companies
Companies in the recombinant factor C assay market are gaining competitive edge over other players by introducing FDA-approved drugs using rFC. They are increasing efforts to experiment with humanized monoclonal antibodies such as galcanezumab for the prevention of migraine in adults. Novel rFC methods are being highly publicized as non-animal alternatives for the assessment of contaminating endotoxins in drugs. Though LAL is considered as the gold standard for endotoxin testing, official declarations by the FDA are validating the efficiency of PyroGene in the recombinant factor C assay market landscape. Thus, accuracy, sensitivity, and specificity of recombinant factor C assay is being considered at par with LAL methods.
Gaining FDA approval for drugs is essential in the recombinant factor C assay market. Advantages of rFC are grabbing the attention of commercial innovators in the field of recombinant technology to explore untapped business potentials.
rFC is ensuring the sustainable evolution of horseshoe crab species. However, it is still unsure whether rFC-based tests outshine LAL assays and other robust test systems. Hence, pharmaceutical test users should increase their efficacy in long-term research studies that validate the efficiency of rFC involving unknown samples and inter-laboratory, -operator, and -lot changes. They should increase research in comparative studies of rFC involving kinetic chromogenic LAL assays that help companies to boost their credibility in the market landscape.
Recombinant Factor C Assay Market: Overview
The global recombinant factor C assay market was valued at ~US$ 13 Mn in 2018 and is projected to expand at a considerable CAGR from 2019 to 2027. Endotoxin detection is a crucial step before the launch of pharmaceutical drugs, medical devices, and biotechnology products for human use. Recombinant factor C assay has been accepted as an alternative to LAL tests, which are widely employed for endotoxin testing. This growing acceptance as an alternative to LAL tests and its inclusion in the regulatory pharmacopoeias would contribute to the growth of the recombinant factor C assay market.
Significant advantages offered by recombinant factor C assays, including cost advantages by aiding in reducing the operator risks by lowering the rate of invalid results and reduction of over 50% of the processing time as compared to the conventional microplate-based LAL tests, contribute to the growth of the recombinant factor C assays market
Productivity of the pharmaceutical industry has been significantly high, with an increase in the number of drugs approved annually. According to the U.S. FDA, in 2018, over 59 new drugs were approved in the U.S. Additionally, increase in demand for personalized medicine aids in the rise in the product approvals. This contributes to the growth of the recombinant factor C assays market.
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111659/2900
Recombinant Factor C Assay Market: Segmentation
The global recombinant factor C assay market has been segmented based on brand, end user, and region
In terms of brand, the global recombinant factor C assay market has been categorized into PyroGene and EndoNext. The PyroGene brand is sub-segmented into PyroGene Bulk rFC (2,880 tests) and PyroGene rFC (192 tests). The EndoNext brand is sub-segmented into EndoZyme II, EndoZyme II GO, and EndoLisa.
Based on end user, the global recombinant factor C assay market has been segregated into pharmaceutical companies, biotechnology companies, medical device companies, and contract research organizations (CROs). The pharmaceutical companies segment dominated the market in 2018, and is likely to remain dominant during the forecast period. Growth of the segment can be attributed to increase in approvals of pharmaceutical drugs globally. In addition, rise in demand for personalized medicines contributes to increase in manufacturing of pharmaceuticals, thereby leading to rise in the number of endotoxin detection tests conducted. This would contribute to the growth of the pharmaceutical companies segment in the recombinant factor C assay market.
Recombinant Factor C Assay Market: Regional Segmentation
In terms of region, the global recombinant factor C assay market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America dominated the global recombinant factor C assay market in 2018 and the trend is expected to continue throughout the forecast period
The recombinant factor C assay market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. Incorporation of recombinant factor C as a recognized endotoxin detection test by pharmacopoeias, and focus on conservation of the Limulus species in Asia Pacific contributes to the growth of the recombinant factor C assay market in the region.
Recombinant Factor C Assay Market: Major Players
Key players operating in the global recombinant factor C assay market are Lonza Group and Hyglos GmbH – a bioMérieux Company
These players are focused on adopting inorganic growth strategies and product launches to strengthen their product portfolio. In June 2018, bioMérieux launched rapid ENDOZYME II GO, a new endotoxin test in the bioMérieux ENDONEXT range of recombinant horseshoe crab factor C assays. bioMérieux entered the market in 2016, through the acquisition of Hyglos, a company engaged in the development of recombinant factor C assays for endotoxin testing.
Key Questions Answered in Global Recombinant Factor C Assay Market Report
- How much sales revenue would be generated by recombinant factor C assay across all regions during the forecast period?
- What are key trends in the global recombinant factor C assay market?
- What are major drivers, restraints, and opportunities in the global recombinant factor C assay market?
- Which regional market is set to expand at the most rapid CAGR during the forecast period?
- Which end user segment would generate the maximum revenue by 2027 and which brand segment would expand at the most rapid CAGR during the forecast period?
Global Recombinant Factor C Assay Market – Segmentation
- PyroGene Bulk rFC (2,880 tests)
- PyroGene rFC (192 tests)
- EndoZyme II
- EndoZyme II GO
- Pharmaceutical Companies
- Biotechnology Companies
- Medical Device Companies
- Contract Research Organizations (CROs)
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
TABLE OF CONTENT
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Acronyms
3. Research Methodology
4. Executive Summary: Global Recombinant Factor C Assay Market
5. Market Overview
5.2. Market Indicators
5.3. Market Dynamics
5.4. Global Recombinant Factor C Assay Market Revenue (US$ Mn) Forecast 2017–2027
5.5. Global Recombinant Factor C Assay Market Outlook
6. Key Insights
6.1. Value Chain Analysis
6.2. Key Industry Events
6.3. Patent Analysis
6.4. Product Features & USPs
6.5. Overview of Pyrogen Testing Products Market
6.5.1. Pyrogen Testing- Service Providers
6.5.2. Pyrogen Testing Products Marketing, by Country/Region
6.6. Overview of Limulus Amoebocyte Lysate (LAL) Tests
6.6.1. Number of Assays Performed
6.6.2. Cost per Assay and Turn Around Time
6.7. Regulatory Scenario, by Country/Region
6.8. Institutes Involved in Research Studies using Horseshoe Crabs
7. Global Recombinant Factor C Assay Market Analysis and Forecast, by Brand
7.2. Global Recombinant Factor C Assay Market Value Share Analysis, by Brand
7.3. Global Recombinant Factor C Assay Market Value Forecast, by Brand, 2017–2027
184.108.40.206. PyroGene Bulk rFC (2,880 tests)
220.127.116.11. PyroGene rFC (192 tests)
18.104.22.168. Endozyme II
22.214.171.124. Endozyme II GO
7.4. Global Recombinant Factor C Assay Market Attractiveness, by Brand
8. Global Recombinant Factor C Assay Market Analysis and Forecast, by End-user
8.2. Global Recombinant Factor C Assay Market Value Share Analysis, by End-user
8.3. Global Recombinant Factor C Assay Market Value Forecast, by End-user, 2017–2027
8.3.1. Pharmaceutical Companies
8.3.2. Biotechnology Companies
8.3.3. Medical Device Companies
8.3.4. Contract Research Organizations (CROs)
8.4. Global Recombinant Factor C Assay Market Attractiveness, by End-user
9. Global Recombinant Factor C Assay Market Analysis and Forecast, by Region
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111659/2900
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us: